The valve gets fixed. The risk doesn't disappear.
TAVR has transformed the treatment of aortic stenosis. Procedural success rates are high and early mortality has fallen sharply — but a successful valve replacement does not guarantee a successful recovery.
Even after a technically flawless procedure, 20–25% of patients are readmitted within 90 days (Abramowitz et al., Circ Cardiovasc Interv 2017), and roughly two-thirds of deaths in this population are non-cardiac (Kolte et al., JACC Cardiovasc Interv 2025, n=36,877) — driven by infection and systemic decline that routine follow-up isn't structured to catch.
days of continuous monitoring from discharge
A repaired valve still leaves a patient exposed. BridgeCare LA enrolls every TAVR patient in continuous Clinical Status Monitoring the day they're discharged, whether or not they already look high-risk.
The program layers hemodynamic monitoring through Vivio, arrhythmia surveillance with an ECG patch across the first month and Kardia through day 90, heart-failure detection from weight, blood pressure, heart rate, and SpO₂ trends, and infection surveillance across precisely the stretch where systemic decline tends to do the most harm while drawing the least scrutiny.
Two things watch for infection at once. Alongside continuous temperature, provider-ordered biomarker testing adds a second, independent read, usually pulled from labs the patient is already scheduled for, so nothing extra is ordered.
Infection gets read two independent ways at once — continuous device-based temperature monitoring alongside provider-ordered biomarker testing — rather than trusting either signal on its own.
TAVR solves the valve. BridgeCare LA extends the visibility, narrows the uncertainty, and makes earlier intervention possible — for everything that comes after.
Deploy this program across Louisiana.
Talk to BridgeCare LA about bringing Post-TAVR Monitoring to your practice or health system.
Book a Consultation